Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 3, 2004, Pages 350-354

  Quan Jr , Walter ^a   Brick, Wendy ^a   Vinogradov, Mikhail ^a   Taylor, W Chris ^a   Khan, Nawazish ^a   Burgess, Russell ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Interleukin 2; Kidney cancer; Lymphokine activated killer cells; Melanoma

Indexed keywords

CORTICOSTEROID; CREATININE; DILTIAZEM; FAMOTIDINE; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BOLUS INJECTION; BONE METASTASIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; KIDNEY CANCER; LIVER METASTASIS; LUNG EDEMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; NAUSEA; NEPHRECTOMY; NEPHROTOXICITY; PRIORITY JOURNAL; RIGOR; STOMATITIS; SURVIVAL TIME; VOMITING;

ADULT; AGED; FEMALE; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; TIME FACTORS;

EID: 3142688266     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/1084978041424972     Document Type: Article

References (22)

1. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am 2000;6(Suppl. 1):S11.
2. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6(Suppl. 1):S55.
3. Hawkins MJ. Interleukin-2 antitumor and effector cell responses. Semin Oncol 1993;20(Suppl. 9):52.
4. Papa MZ, Mule JJ, Rosenberg SA. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: Successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histologic types. Cancer Res 1986;46:4973.
5. Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 1989;7:486.
6. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694.
7. Sondel PM, Kohler PC, Hank JA, et al. Clinical and immunological effects of recombinant interleukin-2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988;48:2561.
8. Sosman JA, Kohler PC, Hank J, et al. Repetitive weekly cycles of recombinant human interleukin-2: Responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 1988;80:60.
9. Sosman JA, Kohler PC, Hank JA, et al. Repetitive weekly cycles of interleukin-2. II Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst 1988;80:1451.
10. Zimmerman RJ, Aukerman SL, Katre NV, et al. Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin-2 in murine tumor models. Cancer Res 1989;49:6521.
11. Dillman RO, Oldham RK, Tauer KW, et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A National Biotherapy Study Group trial. J Clin Oncol 1991;9:1233.
12. Dillman RO, Oldham RK, Barth NM, et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A National Biotherapy Study Group trial. Cancer 1991;68:1.
13. Dillman RO, Wiemann MC, VanderMolen LA, et al. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: A phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group). Cancer Biother Radiopharm 1997;12:249.
14. Dillman RO, Wiemann MC, Bury MJ, et al. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: A phase II trial of the National Biotherapy Study Group. Cancer Biother Radiophar 1997;12:5.
15. Sondel PM. Cellular immunotherapy of cancer: Preclinical and clinical testing utilizing interleukin-2. In: Lotzova E, ed. Interleukin-2 and killer cells in cancer. Boca Raton: CRC Press, 1990:1.
16. Lindsey KR, Rosenberg SA, Sherry RM. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. J Clin Oncol 2000;18:1954.
17. Dillman RO, Church C, Oldham RK, et al. Inpatient continuous infusion interleukin-2 in 788 patients with cancer. Cancer 1993;71:2358.
18. Kikuchi Y, Oomori K, Kizawa I, et al. The effect of cimetidine on natural killer activity of peripheral blood lymphocytes of patients with ovarian carcinoma. Japn J Clin Oncol 1985;15:377.
19. Flodgren P, Sjogren HO. Influence in vitro on NK and K cell activities by cimetidine and indomethacin with and without simultaneous exposure to interferon. Cancer Immun Immunother 1985;19:28.
20. Allen JI, Syropoulos HJ, Grant B, et al. Cimetidine modulates natural killer cell function of patients with chronic lymphocytic leukemia. J Lab Clin Med 1987;109:396.
21. Parshad R, Kapoor S, Gupta SD, et al. Does famotidine enhance tumor-infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. Acta Oncol 2002;41:362.
22. Tsunoda T, Tanimura H, Yamaue H, et al. In vitro augmentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor-infiltrating lymphocytes by famotidine in cancer patients. Int J Immunopharm 1992;14:75.